Alcon stock narrows 2026 outlook after mixed third quarter

Published on 11/13/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock faces a tighter 2026 outlook after mixed third-quarter results. Core earnings rose as sales growth met competitive pressure.

Key takeaways for investors

Alcon generated third-quarter sales of 2.717 billion US dollars, up 5 percent from the prior-year quarter.
Core diluted earnings per share rose 15 percent to 0.91 US dollars, helped by tariff refunds and manufacturing efficiencies.
Alcon now expects 2026 sales growth of approximately 6 percent and narrower ranges for core margin and core earnings growth.

Alcon Inc., CH0432492467, Illustration mit AI erstellt.

Alcon narrowed its 2026 profitability outlook after third-quarter sales growth faced competitive pressure in implantables, while core earnings advanced. In its official November 10 media release, the eye-care company reported results for the period ended September 30, 2026.

Sales growth meets competitive pressure

Third-quarter net sales reached 2.717 billion US dollars, an increase of 5 percent from 2.589 billion US dollars a year earlier. Surgical sales rose 4 percent to 1.480 billion US dollars, although implantables declined 2 percent to 422 million US dollars because of competitive pressure in the United States. Consumables increased 6 percent, while equipment and other sales advanced 11 percent.

Vision Care sales grew 6 percent to 1.237 billion US dollars. Contact lenses increased 4 percent, and ocular health sales rose 8 percent, supported by dry-eye products including Tryptyr and Systane. For the first nine months, total sales rose 7 percent to 8.184 billion US dollars, or 6 percent in constant currency.

Core earnings benefit from one-time items

Reported operating income increased 15 percent to 381 million US dollars, with operating margin at 14.0 percent compared with 12.8 percent a year earlier. Core operating income, a non-IFRS measure, rose 13 percent to 591 million US dollars, while core operating margin reached 21.8 percent from 20.2 percent.

Alcon said the quarter benefited from 58 million US dollars in tariff refunds, manufacturing efficiencies and lower amortization. Core diluted earnings per share rose 15 percent to 0.91 US dollars from 0.79 US dollars. Reported diluted earnings per share increased to 0.54 US dollars from 0.48 US dollars.

The nine-month reported figures were affected by a 402 million US dollar pre-tax, non-cash charge tied to discontinuing the PowerVision programs, alongside efficiency costs and other items. As a result, nine-month diluted earnings per share fell to 0.92 US dollars from 1.53 US dollars, while core diluted earnings per share increased to 2.60 US dollars from 2.29 US dollars.

Outlook range becomes narrower

Alcon now expects 2026 sales growth of approximately 6 percent in constant currency, replacing the previous range of 5 to 7 percent. The expected increase in core operating margin was narrowed to 100 to 150 basis points from 90 to 190 basis points, while core diluted earnings per share growth is now expected at 12 to 14 percent rather than 12 to 15 percent.

Management assumes eye-care markets will grow approximately 3 percent and estimates a full-year net tariff impact of approximately 40 million US dollars after mitigating actions and refunds. Chief Executive David J. Endicott said the company remained on track for its objectives despite specific areas of competitive pressure and highlighted new products, the product pipeline and the acquisition of Neurotech Pharmaceuticals.

Alcon stock traded at 65.69 euros on Lang & Schwarz at 10:39 CET on Friday, November 13.